<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701428</url>
  </required_header>
  <id_info>
    <org_study_id>VGSKAS-12916</org_study_id>
    <secondary_id>FoU Sweden, nr 8751</secondary_id>
    <nct_id>NCT00701428</nct_id>
  </id_info>
  <brief_title>Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment</brief_title>
  <acronym>LosartanPAP</acronym>
  <official_title>Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skaraborg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GÃ¶teborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Skaraborg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is a highly prevalent condition in hypertensive patients. The
      renin-angiotension-aldosterone-system (RAAS) has a central role in blood pressure control. An
      angiotensin-II-antagonist, Losartan, is an effective antihypertensive drug. However, some
      patients respond to this drug worse than the others, and it is a clinical praxis to either
      increase the dosage and/or add another drug. There is limited data regarding the impact of
      antihypertensive drugs in OSA patients, i.e., whether or not OSA may constitute the subgroup
      of therapy-resistent hypertensive patients. In the literature, there is no data, either,
      whether or not CPAP treatment may have an additive blood pressure lowering impact in this
      certain subgroup.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OSA is a highly prevalent condition in hypertensive patients and the prevalence is even
      higher in patients with drug-resistant hypertension. The
      renin-angiotension-aldosterone-system (RAAS) has a central role in blood pressure control. An
      angiotensin-II-antagonist, Losartan, has an effective antihypertensive drug. However, some
      patients respond to this drug worse than the others, and it is a clinical praxis to either
      increase the dosage and/or add another drug. There is limited data regarding the impact of
      antihypertensive drugs in OSA patients, i.e., whether or not OSA may constitute the subgroup
      of therapy-resistent hypertensive patients. In the literature, there is no data, either,
      whether or not CPAP treatment may have an additive blood pressure lowering impact in this
      certain subgroup. The investigators will include 90 otherwise healthy, untreated hypertensive
      men and women(age 50-69 yrs, Body-Mass-Index &lt;35 kg/m2; 60 patients with OSA, 30 non-OSA) as
      described above. Before start of treatment, fasting blood samples will be drawn regarding the
      neuroendocrine hormones (adrenaline, noradrenaline, plasma renin activity, angiotensin
      II,aldosterone, pro-BNP) and cardiovascular biomarkers (CRP,interleukines, cytokines). All
      subjects will start with Losartan 50 mg and 24 h- blood-pressure response and blood sample
      analysis will be compared between OSA and non-OSA subjects after 6 weeks of treatment. In the
      second 6-week period, all subjects will continue with Losartan while the half of the OSA
      group (n=30) will be randomized to CPAP and the other 30 patients will continue with Losartan
      only.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 h blood pressure (mean blood pressure; mmHg)</measure>
    <time_frame>Changes from Baseline in 24 h BP at 6 and 12 weeks, respectively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of sympathetic activity, RAAS-activity, cardiovascular biomarkers</measure>
    <time_frame>Changes from Baseline in Biomarkers at 6 and 12 weeks, respectively</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hypertension</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypertensive Men and Women Without OSA on Losartan (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypertensive Men and Women With OSA on Losartan (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 50 mg daily during 6 + 6 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP during the second 6 week-period</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Auto-CPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index &lt;35 kg/m2

          -  Systolic Blood Pressure &gt;=140 mmHg and/or Diastolic Blood Pressure &gt;=95 mmHg

          -  No known clinical disease except hypertension

          -  No cardiovascular medication

          -  Apnea-Hypopnea Index &lt; 5/h (no OSA), or Apnea Hypopnea Index &gt;=15/h (OSA)

        Exclusion Criteria:

          -  Manifest diabetes, liver- or kidney disease Signs of atrial fibrillation or former
             myocardial infarction at electrocardiogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuksel Peker, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skaraborg Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skaraborg Hospital</name>
      <address>
        <city>Skoevde</city>
        <state>West Gotaland</state>
        <zip>SE 51485</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skaraborg Hospital</investigator_affiliation>
    <investigator_full_name>Yuksel Peker</investigator_full_name>
    <investigator_title>MD, PhD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Sleep Apnea</keyword>
  <keyword>Angiotensin II antagonist</keyword>
  <keyword>CPAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

